论文部分内容阅读
目的研究急性髓系白血病(AML)患者初诊与复发时的基因表达谱差异,探讨难治性AML的发病机制。方法应用Agilent Human1B寡核苷酸基因芯片,动态检测了3例AML-M2a患者初诊、复发时骨髓单个核细胞的基因表达谱差异。结果在检测的20173个基因中,有10个基因在3例患者初诊、复发时共同差异表达,其中7个基因在复发时均共同上调,3个基因在复发时均表现下调。结论DAPK1等10个基因的表达变化可能与AML-M2a发病和复发有关,这些新基因的发现可能对早期诊断难治性AML具有重要价值,同时为难治性AML提供新的治疗靶点。
Objective To study the difference of gene expression profiles between newly diagnosed and relapsed acute myeloid leukemia (AML) patients and explore the pathogenesis of refractory AML. Methods The gene expression profile of bone marrow mononuclear cells in newly diagnosed and relapsed AML-M2a patients was dynamically detected by Agilent Human1B oligonucleotide microarray. Results Among the 3,773 genes examined, 10 were newly diagnosed in 3 patients and were differentially expressed in relapse. Seven of them were upregulated in relapse and all three genes were downregulated in relapse. Conclusions The changes of DAPK1 and other 10 genes may be related to the pathogenesis and recurrence of AML-M2a. The discovery of these new genes may be of great value in the early diagnosis of refractory AML and provide a new therapeutic target for refractory AML.